Publications by authors named "Pratiti Bandopadhayay"

Artificial intelligence (AI) applied to brain magnetic resonance imaging (MRI) has the potential to improve disease diagnosis and management but requires algorithms with generalizable knowledge that can perform well in a variety of clinical scenarios. The field has been constrained, thus far, by limited training data and task-specific models that do not generalize well across patient populations and medical tasks. Foundation models, by leveraging self-supervised learning, pretraining, and targeted adaptation, present a promising paradigm to overcome these limitations.

View Article and Find Full Text PDF

Central nervous system neuroblastoma with FOXR2 activation (NB-FOXR2) is a high-grade tumor of the brain hemispheres and a newly identified molecular entity. Tumors express dual neuronal and glial markers, leading to frequent misdiagnoses, and limited information exists on the role of FOXR2 in their genesis. To identify their cellular origins, we profiled the transcriptomes of NB-FOXR2 tumors at the bulk and single-cell levels and integrated these profiles with large single-cell references of the normal brain.

View Article and Find Full Text PDF

Background: Postoperative recurrence risk for pediatric low-grade gliomas (pLGGs) is challenging to predict by conventional clinical, radiographic, and genomic factors. We investigated if deep learning of MRI tumor features could improve postoperative pLGG risk stratification.

Methods: We used pre-trained deep learning (DL) tool designed for pLGG segmentation to extract pLGG imaging features from preoperative T2-weighted MRI from patients who underwent surgery (DL-MRI features).

View Article and Find Full Text PDF
Article Synopsis
  • A study conducted at Dana-Farber/Boston Children's Cancer and Blood Disorders Center focused on classifying pediatric solid tumor diagnoses and analyzing genomic mutations to improve clinical trial design and treatment options.
  • Over 6.5 years, the research included 888 pediatric cancer patients, revealing that 33% had genomic variants that aligned with precision oncology trials, while 14% received targeted therapies.
  • The findings stress the significance of using genomic data for enhancing treatment strategies and the necessity for data sharing, particularly for addressing rare pediatric cancers in clinical settings.
View Article and Find Full Text PDF

Pediatric glioma recurrence can cause morbidity and mortality; however, recurrence pattern and severity are heterogeneous and challenging to predict with established clinical and genomic markers. Resultingly, almost all children undergo frequent, long-term, magnetic resonance (MR) brain surveillance regardless of individual recurrence risk. Deep learning analysis of longitudinal MR may be an effective approach for improving individualized recurrence prediction in gliomas and other cancers but has thus far been infeasible with current frameworks.

View Article and Find Full Text PDF

Pediatric low-grade glioma (pLGG) is the most common childhood brain tumor group. The natural history, when curative resection is not possible, is one of a chronic disease with periods of tumor stability and episodes of tumor progression. While there is a high overall survival rate, many patients experience significant and potentially lifelong morbidities.

View Article and Find Full Text PDF

Purpose To develop and externally test a scan-to-prediction deep learning pipeline for noninvasive, MRI-based mutational status classification for pediatric low-grade glioma. Materials and Methods This retrospective study included two pediatric low-grade glioma datasets with linked genomic and diagnostic T2-weighted MRI data of patients: Dana-Farber/Boston Children's Hospital (development dataset, = 214 [113 (52.8%) male; 104 (48.

View Article and Find Full Text PDF

Background: Cellular senescence can have positive and negative effects on the body, including aiding in damage repair and facilitating tumor growth. Adamantinomatous craniopharyngioma (ACP), the most common pediatric sellar/suprasellar brain tumor, poses significant treatment challenges. Recent studies suggest that senescent cells in ACP tumors may contribute to tumor growth and invasion by releasing a senesecence-associated secretory phenotype.

View Article and Find Full Text PDF
Article Synopsis
  • Pediatric high-grade gliomas (pHGG) are really tough brain tumors that usually can't be cured and often have mutations in a gene called histone H3.3.
  • These mutations cause problems with how genes work and can make the brain cells unstable.
  • Researchers found that a DNA repair enzyme called PNKP helps the cancer cells survive, which could be a new way to create treatments specifically for these mutated cells.
View Article and Find Full Text PDF

A hallmark of high-risk childhood medulloblastoma is the dysregulation of RNA translation. Currently, it is unknown whether medulloblastoma dysregulates the translation of putatively oncogenic non-canonical open reading frames (ORFs). To address this question, we performed ribosome profiling of 32 medulloblastoma tissues and cell lines and observed widespread non-canonical ORF translation.

View Article and Find Full Text PDF

Within the last few decades, we have witnessed tremendous advancements in the study of pediatric low-grade gliomas (pLGG), leading to a much-improved understanding of their molecular underpinnings. Consequently, we have achieved successful milestones in developing and implementing targeted therapeutic agents for treating these tumors. However, the community continues to face many unknowns when it comes to the most effective clinical implementation of these novel targeted inhibitors or combinations thereof.

View Article and Find Full Text PDF
Article Synopsis
  • - Recent clinical trials for H3K27-altered diffuse midline gliomas (DMGs) are showing promising results, indicating potential advancements in treatment.
  • - The text identifies three key challenges: improving experimental models to include immune and brain-specific factors, fostering collaboration between researchers, clinicians, and the industry, and optimizing clinical processes like biopsy and drug delivery.
  • - Emphasizes that extensive collaboration is crucial for enhancing our understanding of DMGs, as well as improving diagnostics and therapies for these tumors.
View Article and Find Full Text PDF
Article Synopsis
  • * pLGG is viewed as a chronic condition, emphasizing the significance of quality of life and functional outcomes, along with advancements in understanding its biological mechanisms for developing targeted therapies.
  • * The International Pediatric Low-Grade Glioma Coalition (iPLGGc) reviews the latest information on pLGG, including its epidemiology, treatment options, and ongoing challenges, while introducing additional research papers on preclinical models, clinical trial frameworks, and tumor resistance issues.
View Article and Find Full Text PDF

Background: Recurrent brain tumors are the leading cause of cancer death in children. Indoleamine 2,3-dioxygenase (IDO) is a targetable metabolic checkpoint that, in preclinical models, inhibits anti-tumor immunity following chemotherapy.

Methods: We conducted a phase I trial (NCT02502708) of the oral IDO-pathway inhibitor indoximod in children with recurrent brain tumors or newly diagnosed diffuse intrinsic pontine glioma (DIPG).

View Article and Find Full Text PDF

Purpose: To develop and externally validate a scan-to-prediction deep-learning pipeline for noninvasive, MRI-based BRAF mutational status classification for pLGG.

Materials And Methods: We conducted a retrospective study of two pLGG datasets with linked genomic and diagnostic T2-weighted MRI of patients: BCH (development dataset, n=214 [60 (28%) BRAF fusion, 50 (23%) BRAF V600E, 104 (49%) wild-type), and Child Brain Tumor Network (CBTN) (external validation, n=112 [60 (53%) BRAF-Fusion, 17 (15%) BRAF-V600E, 35 (32%) wild-type]). We developed a deep learning pipeline to classify BRAF mutational status (V600E vs.

View Article and Find Full Text PDF

Purpose: Treatment of wingless (WNT)-activated medulloblastoma (WNT+MB) with surgery, irradiation (XRT), and chemotherapy results in excellent outcomes. We studied the efficacy of therapy de-intensification by omitting XRT entirely in children with WNT+MB.

Patients And Methods: Tumors were molecularly screened to confirm the diagnosis of WNT+MB.

View Article and Find Full Text PDF

Spheroid culture systems have allowed in vitro propagation of cells unable to grow in canonical cell culturing conditions, and may capture cellular contexts that model tumor growth better than current model systems. The insights gleaned from genome-wide clustered regularly interspaced short palindromic repeat (CRISPR) screening of thousands of cancer cell lines grown in conventional culture conditions illustrate the value of such CRISPR pooled screens. It is clear that similar genome-wide CRISPR screens of three-dimensional spheroid cultures will be important for future biological discovery.

View Article and Find Full Text PDF

A hallmark of high-risk childhood medulloblastoma is the dysregulation of RNA translation. Currently, it is unknown whether medulloblastoma dysregulates the translation of putatively oncogenic non-canonical open reading frames. To address this question, we performed ribosome profiling of 32 medulloblastoma tissues and cell lines and observed widespread non-canonical ORF translation.

View Article and Find Full Text PDF

Background: Pediatric low-grade gliomas (pLGGs) are the most common central nervous system tumor in children, characterized by RAS/MAPK pathway driver alterations. Genomic advances have facilitated the use of molecular targeted therapies, however, their long-term impact on tumor behavior remains critically unanswered.

Methods: We performed an IRB-approved, retrospective chart and imaging review of pLGGs treated with off-label targeted therapy at Dana-Farber/Boston Children's from 2010 to 2020.

View Article and Find Full Text PDF

Purpose: Anaplastic lymphoma kinase (ALK) aberrations have been identified in pediatric-type infant gliomas, but their occurrence across age groups, functional effects, and treatment response has not been broadly established.

Experimental Design: We performed a comprehensive analysis of ALK expression and genomic aberrations in both newly generated and retrospective data from 371 glioblastomas (156 adult, 205 infant/pediatric, and 10 congenital) with in vitro and in vivo validation of aberrations.

Results: ALK aberrations at the protein or genomic level were detected in 12% of gliomas (45/371) in a wide age range (0-80 years).

View Article and Find Full Text PDF